Medications & Psychiatry
Resources

 email page    print page

All Topic Reviews
Psychiatry Under the InfluenceAlternatives Beyond PsychiatryAmerican MadnessAmerican PsychosisAn Unquiet MindAntipsychiatryBad PharmaBefore ProzacBetter Than ProzacBiological PsychiatryBlack Man in a White CoatBlaming the BrainBrain Science and Psychological DisordersBrainwashedClinical Psychopharmacology Made Ridiculously SimpleComfortably NumbCompassion and Healing in Medicine and SocietyComplete Mental HealthConcise Guide to PsychopharmacologyCrackedCultural FormulationDeconstructing PsychosisDemystifying PsychiatryDiagnosing the Diagnostic and Statistical Manual of Mental DisordersDiagnosis: SchizophreniaDiagnostic Issues in Depression and Generalized Anxiety DisorderDimensional Models of Personality DisordersDisordered Personalities and CrimeDoctoring the MindDoctors of DeceptionDruggedDrugs for LifeEmpirical Ethics in PsychiatryEssential PsychopharmacologyEssential Psychopharmacology of Depression and Bipolar DisorderEssentials of Psychiatric DiagnosisEsssential Philosophy of PsychiatryEthics in PsychiatryEvidence-Based Treatment of Personality DysfunctionFinding the Right Psychiatrist:Forces of HabitHandbook of Clinical Psychopharmacology for TherapistsHappy Pills in AmericaHealing the Soul in the Age of the BrainHelping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional ProblemsHerbs for the MindHigh PriceHippocrates CriedHistory of Psychiatry and Medical PsychologyHookedHuman TrialsInfectious MadnessInspired SleepIntoxicating MindsIs It Me or My Meds?Let Them Eat ProzacLife-Threatening Effects of Antipsychotic DrugsLitLiving with Bipolar DisorderMad in AmericaMad ScienceMalignant SadnessMedicating ChildrenMedicating Modern AmericaMoments of EngagementMommy I'm Still in HereNatural Healing for DepressionNot CrazyOrdinarily WellOur Daily MedsOverdosed AmericaPathologist of the MindPediatric PsychopharmacologyPediatric PsychopharmacologyPediatric PsychopharmacologyPharmacracyPharmageddonPharmageddonPoets on ProzacPower HerbsPowerful MedicinesPrescriptions for the MindProfits Before People?Prozac and the New AntidepressantsProzac As a Way of LifeProzac BacklashProzac DiaryProzac on the CouchPsychiatric DiagnosisPsychiatric HegemonyPsychiatrists and Traditional HealersPsychiatry and EmpirePsychiatry and the Business of MadnessPsychiatry as Cognitive NeurosciencePsychiatry at a GlancePsychiatry in PrisonsPsychiatry ReconsideredPsychopathyPsychopharmacology Problem SolvingPsychotropic Drug Prescriber's Survival GuidePsychotropic Drugs And Popular CulturePsychotropic Drugs: Fast FactsRaising Generation RxRe-Visioning PsychiatryRecovery from SchizophreniaReligious and Spiritual Issues in Psychiatric DiagnosisRitalin NationRunning on RitalinRutter's Child and Adolescent PsychiatrySaving NormalSchizophreniaShock TherapyShock TherapyShould I Medicate My Child?ShrinksSide EffectsStraight Talk about Psychiatric Medications for KidsSuccessful PsychopharmacologySuffer the ChildrenTaking America Off DrugsTalking Back to ProzacTextbook of Cultural PsychiatryThe $800 Million PillThe Age of AnxietyThe Anti-Depressant Fact BookThe Antidepressant EraThe Antidepressant SolutionThe Antidepressant Survival ProgramThe Big FixThe Book of WoeThe Complete Guide to Herbal MedicinesThe Conceptual Evolution of DSM-5The CorrectionsThe Creation of PsychopharmacologyThe Cult of PharmacologyThe Dream DrugstoreThe Emperor's New DrugsThe Essential Guide to Prescription Drugs 2005The Essential Guide to Prescription Drugs 2006The Making of DSM-III®The Medicated ChildThe Medication QuestionThe Merck DruggernautThe Mind/Mood Pill BookThe Natural Pharmacist : Natural Health Bible from the Most Trusted Alternative Health Site in the World The Pill BookThe Pill Book Guide to Natural MedicinesThe PlaceboThe Rise and Fall of the Biopsychosocial ModelThe Therapist's Guide to PsychopharmacologyThe Therapist's Guide to Psychopharmacology, Revised EditionThe Truth About the Drug CompaniesThe Use and Misuse of Psychiatric DrugsThe World of CaffeineToxic PsychiatryTrouble in MindTry to RememberTry to RememberUnderstanding Physician-Pharmaceutical Industry InteractionsUnhingedVoluntary MadnessWarning: Psychiatry Can Be Hazardous to Your Mental HealthWhat Is Mental Illness?What Psychiatry Left Out of the DSM-5What Works for Whom?Will@epicqwest.comWomen, Madness and MedicineYour Drug May Be Your Problem

Related Topics
 Psychiatry Under the InfluenceReview - Psychiatry Under the Influence
Institutional Corruption, Social Injury, and Prescriptions for Reform
by Robert Whitaker and Lisa Cosgrove
Palgrave Macmillan, 2015
Review by E. James Lieberman
Mar 8th 2016 (Volume 20, Issue 10)

 

This is a thoughtful, well-documented, critique of American psychiatry by journalist Whitaker (Mad in America and Anatomy of an Epidemic) and psychologist Cosgrove (U. Massachusetts; co-author, The Ethics of Pharmaceutical Industry Influence in Medicine). Among 11 chapters are "Economies of Influence," "Psychiatry's New Drugs," and "A Society Harmed." There are 16 helpful figures and tables, e.g., American Psychiatric Association (APA) annual revenues 1980-2012. The Diagnostic and Statistical Manual of Mental Disorders(DSM) first appeared in 1952, has worldwide influence and is a source of income for the APA. 

 

Whitaker and Cosgrove cite DSM-III, released in 1980, as the turning point in American psychiatry from the psychoanalytic causal paradigm to one of symptoms--single and multiple. Modern psychiatry has evolved from a Freudian psychoanalytic orientation to one that catalogs deviant thinking, emotion and behavior. Pharmacology 

 

The authors emphasize the growing influence of drug companies on psychiatric practice and teaching. Thus, "During the past 35 years, psychiatry has transformed American culture. It has changed our view of childhood and what is expected of 'normal' children, so much so that more than five percent of school-age youth now take a psychotropic drug daily." Many infants have been exposed to antidepressants in utero, and many elderly Americans in nursing homes are given these drugs even without a psychiatric diagnosis. Spending on psychiatric drugs rose from $800 million in 1985 to $40 billion in 2011 (pp. 7, 9).

 

The authors begin with history, going back to Benjamin Rush in 1812 and the founding of a psychiatric organization in 1844 that became the APA. By 1885, there were eight kinds of insanity recognized: mania, melancholia, monomania, dementia, general paralysis of the insane, epilepsy, toxic insanity and congenital mental deficiency. After 1900, inpatients in the U.S. were likely to be demented, epileptic, retarded, syphilitic or alcoholic. By1918 a standardized nosology listed 22 categories of illness, of which all but two were attributed to biological causes: syphilis, alcohol, arteriosclerosis, etc. Psychoanalysis, which began to attract physicians in the 1920s, dominated psychiatric training for decades, but by 1956, Thorazine and Miltown were in the picture. Psychiatry training residencies then neared 3,000, up from 758 a decade earlier. The profession ceded therapy to others. By 1977 clinical psychologists gained full status as psychotherapists without need for medical supervision. 

 

The DSM-III of 1980, almost 500 pages, listed 265 disorders. Psychoanalysis became less fashionable as insurance covered only short-term therapy. Psychiatrists donned a metaphorical white coat and wrote more prescriptions, emphasizing medical causes and cures. Pharmaceutical companies thrived with the introduction of new drugs--Xanax, Prozac and other anti-depressants, all heavily advertised. APA revenues went up with ads for drugs in its journals. The industry sponsored symposia at meetings and developed continuing education programs. 

 

In 1985, Fred Gottlieb, M.D., then APA treasurer, expressed dismay about "millions of dollars of drug house money" coming in for ads, exhibits, lectures, and social events. "We seem to discount available data that drug advertising promotes irrational prescribing practices...We persist in ignoring an inherent conflict of interest." (p. 37) The APA board did nothing; some members praised the partnership with industry. DSM-5 came out in 2013: over two-thirds of its task force had received funds from drug companies. (p. 40). 

 

DSM codes are part of billing for insurance payments. While "reliable," the diagnoses lack validity and are not useful for research. Researchers have a nomenclature, "but probably the wrong one" said Nancy Andreasen, M.D., former editor of the American Journal of Psychiatry, in 2007. (p. 60) Whitaker and Cosgrave allege that "the APA helped promote a false notion--that psychiatric drugs corrected chemical imbalances in the brain." (p. 62) 

 

After Valium was launched in 1961--for over a decade the most prescribed medication in the Western world--came Xanax (1981). But benzodiazepines, while reducing anxiety, were addictive. Their use dropped from 103 to 71 million prescriptions in five years (1975-80). Then the diagnosis Panic Disorder gave new impetus to Xanax. In double-blind trials, patients on the drug had fewer symptoms after a month than the control group, but in the second month the placebo group caught up! Those taking the drug got worse in the tapering-off phase while the placebo group improved. Investigators fudged the report by reporting only the first week's data. Evidently, Panic Disorder was invented to promote a drug that was worse than useless. 

 

Prozac (fluoxetine), the next "wonder drug", had major flaws in protocols submitted to the FDA by manufacturer Eli Lilly. Zoloft, Pfizer's anti-depressant, was similarly promoted with cherry-picked protocols. FDA data on Celexa, Paxil, Zyprexa and Seroquel showed little difference between drug and placebo, but supportive studies went unpublished. The authors call this "institutional corruption," a partnership between psychiatry and industry that compromised ethical medical practice for private profit.

 

Whitaker and Cosgrove have a dim view of DSM, with its collection of some 300 psychiatric diagnoses. There are no categories of illness based on etiology or mechanism of pathology, but the APA claims brain involvement whenever possible. Thus with the rise of Attention Deficit Hyperactivity Disorder, methylphenidate (Ritalin), was prescribed because stimulants were known to calm hyperactive children. By 1980 150,000 young patients were taking the drug.  By 1994 ADHD was estimated to affect up to 5% of children. After the Ritalin patent expired came Adderall, Concerta, and Strattera, with many paid ads in professional journals. By 2012, 10% of American children and adolescents had the diagnosis and 3.5 million were on methylphenidate. 

 

U.S. adults filled 264 million prescriptions for antidepressants in 2001, up from 30 million in 1980 and greater than any other class of medication. (p. 93) In 2004 the FDA revealed that 12 of 15 pediatric trials of SSRI showed no benefit in trials and found a doubling of suicidal thoughts among teens. Published articles showed only benefits; failures were not published. The majority of psychiatrists working on DSM-5 had financial ties to drug companies. The authors conclude:

 

"DSM-5--from a commercial perspective--will provide a diagnostic rationale for treating more children with an antipsychotic; more teenagers and adults with a stimulant; more menstruating women with an SSRI...more teenagers and other young adults seen as 'pre-psychotic' with an antipsychotic; and more forgetful older folks with a drug of a type yet to be determined." (p.113) 

 

Spending on psychiatric drugs in the U.S. jumped from $800 million in 1987 to over $35 billion in 2010. The influence and power of the pharmaceutical industry is obvious, but the guild factor in psychiatry can be corrupting (133).The APA first published Clinical Practice Guidelines (CPGs) in 1991, and since then over a dozen more. 

 

Over the last 20 years most academic leaders in psychiatry have had industry ties. Psychiatric CPG panels allowed--indeed, invited--conflicts of interest. Clinical trials should be objective, yet negative studies of antidepressants were not published. APA did not report that antidepressants beat placebo only with a small group of very depressed patients, as reported by psychologist Irving Kirsch. (PLOS Med 5, 2008;, 260-268)

 

"Our society, over the past 35 years, has organized itself in response to a narrative told by American psychiatry that was, in so many of its details, misleading. Our understanding of the biology of mental disorders, our use of psychiatric drugs, our spending on psychiatric services, and even our social policies arise from a story that has been shaped by guild and pharmaceutical interests, as opposed to a narrative told by a medical profession that has shown an adherence to scientific principles and a commitment--at all times--to the best interests of patients." (p. 155)

 

Psychiatrists are only four percent of U.S. physicians:  most prescriptions of psychotropic drugs come from other physicians.  The authors sympathize with psychiatrists who feel betrayed by APA leadership. Drug ads in the monthly journal and bi-weekly magazine support the organization. 

 

As a lifetime APA member I am dismayed by our institutional dependence on drugs. I hope most APA members will view this critical book as constructive and much-needed. The U.S.is the only country that allows prescription drugs to be advertised to the public on television. Older drugs--generics--are less costly and safer: they have a track record. American Physicians and their professional organizations have an ethical obligation to educate patients targeted with television ads, who assume that newer must be better. 

 

© 2016 E James Lieberman

 

E James Lieberman, M.D., M.P.H., Clin. Prof. Psychiatry, George Washington University, ejl@gwu.edu


Share

Welcome to MHN's unique book review site Metapsychology. We feature over 7800 in-depth reviews of a wide range of books and DVDs written by our reviewers from many backgrounds and perspectives. We update our front page weekly and add more than thirty new reviews each month. Our editor is Christian Perring, PhD. To contact him, use one of the forms available here.

Can't remember our URL? Access our reviews directly via 'metapsychology.net'


Metapsychology Online reviewers normally receive gratis review copies of the items they review.
Metapsychology Online receives a commission from Amazon.com for purchases through this site, which helps us send review copies to reviewers. Please support us by making your Amazon.com purchases through our Amazon links. We thank you for your support!


Join our e-mail list!: Metapsychology New Review Announcements: Sent out monthly, these announcements list our recent reviews. To subscribe, click here.

Interested in becoming a book reviewer for Metapsychology? Currently, we especially need thoughtful reviewers for books in fiction, self-help and popular psychology. To apply, write to our editor.

Metapsychology Online Reviews

Promote your Page too

Metapsychology Online Reviews
ISSN 1931-5716